Kineta Inc (KANT) - News Archive

: Kineta, a biotechnology company focused on developing innovative therapies for cancer and other diseases, recently presented updated clinical results from its ongoing Phase 1/2 VISTA101 study of KVA12123 at the Societ...

In a significant milestone for cancer research and treatment, Kineta Inc. has announced the completion of patient enrollment in the monotherapy arm of its VISTA-101 Phase 1 clinical study, aimed at evaluating its invest...

In a significant development for its ongoing pipeline of innovative therapeutic solutions, Kineta, Inc. has announced the extension of its exclusivity and right of first offer agreement with TuHURA Biosciences concernin...

In a significant development for the biotechnology sector, Kineta, Inc. (Nasdaq: KTA) has announced its transition from the Nasdaq to the OTC (Over-The-Counter) Markets. This strategic move comes as the company aims to...